Ragosa Mark

Insider·Kiniksa Pharmaceuticals International, plc·KNSA·Insider since 2025·Form 4 filings: 15
Trades YTD
3
Trades (12m)
7
Net position
Current holdings
P-code buys (12m)
0
Cluster
None

Transaction history · last 12 months

7 transactions
09 Feb 2026
SOLD
$KNSA
8,731
$43.72
S
09 Feb 2026
SOLD
$KNSA
9,114
$42.85
S
08 Jan 2026
SOLD
$KNSA
12,000
$41.89
S
08 Dec 2025
SOLD
$KNSA
42,841
$41.49
S
12 Nov 2025
SOLD
$KNSA
19,900
$40.94
S
28 Oct 2025
SOLD
$KNSA
100
$41.00
S
04 Aug 2025
SOLD
$KNSA
18,889
$32.89
S

Transaction codes: P open-market purchase · S sale · M option exercise · A grant.

Cluster context · Kiniksa Pharmaceuticals International, plc

last 30 days

No active insider cluster at Kiniksa Pharmaceuticals International, plc in the last 30 days. Mark's recent transactions appear in the section above.

Convergence · Pattern Engine ships in v1.1

30-day window
In development

Convergence participation lands with the Pattern Engine.

Once the Pattern Engine ships, this section will list every active convergence event Mark is named in — the hedge funds and Congress members on the same name, the 30-day window, and the combined position size.

Context

Form 4 background

Form 4 filings are required within two business days of any insider transaction by an officer, director, or 10%+ shareholder. Open-market purchases (transaction code P) are the most signal-rich because they indicate the insider is paying market price with personal cash — as distinct from option exercises, scheduled sales, or compensation grants. Cluster buying — three or more insiders of the same company buying open-market shares in a 30-day window — has historically been one of the strongest positive insider-trading signals in the academic literature.

Source data: SEC EDGAR · Form 4 filings · Last refreshed 10:39 UTC.